P lasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor expressed by vascular endothelial cells, vascular smooth muscle cells (SMCs), and several other cell types.
1 PAI-1 is present in plasma and the extracellular matrix (ECM) of blood vessels, where it rapidly inhibits tissue-type plasminogen activator and urinary-type plasminogen activator, which downregulates plasmin formation and fibrinolysis. Complete deficiency of PAI-1 produces a bleeding disorder, 2 whereas elevated plasma levels of PAI-1 are associated with thrombotic disorders. [3] [4] [5] Although its primary function seems to be the regulation of fibrinolysis, PAI-1 also regulates cell migration, which plays a critical role in vascular remodeling, including pathological neointimal hyperplasia. 6 PAI-1 decreases cell migration by inhibiting pericellular plasmin formation and binding to vitronectin in the ECM, thereby blocking vitronectin's binding interactions with α V β 3 integrin and the urinary-type plasminogen activator receptor. [7] [8] [9] [10] Conversely, PAI-1 exerts a pro-migratory effect by binding to low-density lipoprotein receptor-related protein 1 (LRP1) and activating a Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. 11 Consistent with its opposing effects on cell migration in vitro, PAI-1 has been shown to either inhibit [12] [13] [14] or promote (EC) migration in vitro and vascular wall remodeling in vivo.
Given the potential of PAI-1 to either promote or inhibit SMC migration and considering the central role of SMC migration in pathological vascular remodeling, including arterial restenosis and vein graft intimal hyperplasia, it is critical to determine the effects of pharmacological PAI-1 inhibition on SMC migration. It is equally important to determine the effects of pharmacological PAI-1 inhibition on EC migration because an intact, functional endothelium is essential to maintain vascular health. Therefore, the goals of this study were to examine the effects of PAI-039 (tiplaxtinin), a highly specific and wellcharacterized inhibitor of PAI-1, 28 on SMC and EC migration under physiologically relevant conditions in vitro and arterial and venous remodeling in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

PAI-039 Inhibits SMC Migration
We studied the migration of SMCs through 3-dimensional collagen matrices in the presence or absence of PAI-039. PAI-039 significantly inhibited migration of wild-type (WT) murine SMCs when present in concentrations ≥17.5 μM ( Figure 1A and 1C) . PAI-039 also inhibited the migration of human coronary artery SMCs through collagen ( Figure  IA in the online-only Data Supplement). However, PAI-039 did not inhibit migration of SMCs isolated from pai1 −/− mice ( Figure 1B and 1C) , suggesting that the antimigratory effect of PAI-039 was due specifically to PAI-1 inhibition. PAI-039 had no significant effect on proliferation of WT SMCs ( Figure  IB in the online-only Data Supplement), suggesting that the reduced migration of PAI-039-treated cells was not mediated by an antimitogenic effect. Addition of a mixture of ECM proteins (MaxGel ECM) or purified vitronectin to collagen gels increased SMC migration ( Figure II in the online-only Data Supplement), but did not blunt the antimigratory effect of PAI-039 ( Figure 1 D-1E ). These results suggest that PAI-039 inhibits SMC migration under physiological conditions, including in the presence of vitronectin, which binds PAI-1 and reduces its susceptibility to inhibition by PAI-039.
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PAI-039 Does Not Inhibit EC Migration
We next studied the effect of PAI-039 on EC migration in vitro, using a 2-dimensional scratch assay. Contrary to its inhibitory effect on SMCs, PAI-039 had no significant effect on human aortic EC (AEC) migration ( Figure III in the onlineonly Data Supplement).
PAI-039 Inhibits STAT-1 Signaling in SMCs
PAI-1 induces cell migration via an LRP1-dependent pathway involving STAT-1 nuclear translocation. 11 However, the effects of PAI-1 and PAI-1 inhibition on STAT-1 phosphorylation have not been investigated previously. Therefore, human coronary artery SMCs were incubated in the presence or absence of recombinant wild-type PAI-1 (PAI-1-WT), and STAT-1 phosphorylation was analyzed by Western blotting. PAI-1-WT significantly increased STAT-1 phosphorylation at Tyr 701 ( Figure 2A ). We also studied the effect of PAI-1 inhibition on STAT-1 phosphorylation by incubating human coronary artery SMCs in the presence or absence of PAI-039. PAI-039 significantly decreased the level of constitutive STAT-1 phosphorylation in SMCs ( Figure 2B ). To explore effects of PAI-039 on STAT-1 intracellular trafficking, we treated murine arterial SMCs and AECs with PAI-1-WT and analyzed STAT-1 nuclear translocation by fluorescence immunohistochemistry/confocal scanning laser microscopy. PAI-1-WT induced nuclear translocation of STAT-1 in SMCs, but not in AECs (Figure 3 ). PAI-039 blocked the capacity of PAI-1-WT to induce STAT-1 nuclear translocation in SMCs, but had no discernable effect on STAT-1 signaling in AECs. LRP1 gene and protein expression were markedly lower in AECs than in SMCs ( Figure IV in the online-only Data Supplement), suggesting that the resistance of ECs to the antimigratory effect of PAI-039 may be explained by a very low level of expression of LRP1. PAI-039 blocked PAI-1-WT-induced STAT-1 nuclear translocation in WT mouse embryonic fibroblasts, but there was no discernable effect of PAI-1-WT or PAI-039 on STAT-1 nuclear translocation in LRP1-deficient mouse embryonic fibroblasts ( Figure 3 ). Furthermore, recombinant PAI-1-AK, a recombinant PAI-1 mutant that promotes cell migration by binding to LRP1, but not vitronectin, 32 significantly increased migration of WT mouse embryonic fibroblasts, but not LRP1-deficient mouse embryonic fibroblasts (Figure V in the onlineonly Data Supplement). Together, these results suggest that the differential effects of pharmacological PAI-1 inhibition on SMC versus EC migration are mediated by a distinct difference in the expression of LRP1 and downstream JAK/STAT-1 signaling between these 2 cell types.
PAI-039 Inhibits Intimal Hyperplasia
To examine the effects of PAI-039 in vivo, we subjected mice to carotid artery ligation, which induces formation of an SMCrich neointima proximal to the site of vascular occlusion. 33 We used pluronic gel to deliver PAI-039 (n=5) or vehicle control (n=5) to the surface of ligated carotid arteries. In addition, mice received PAI-039 or vehicle control by intraperitoneal injection for 4 weeks after surgery. PAI-039 significantly inhibited neointima formation and percent lumen stenosis, but not vessel total cross-sectional area ( Figure 4 ). Immunohistochemical analysis revealed that there was negligible macrophage (Mac-3-positive cell) invasion into the neointima of either experimental group at this time point (data not shown), consistent with a prior study. 33 We also studied the effects of pharmacological PAI-1 inhibition on the intimal hyperplasia that develops in segments of inferior vena cava after they are grafted into the transected carotid arteries of recipient mice. 34 Reverse transcriptase polymerase chain reaction analysis revealed that PAI-1 gene expression was increased >2-fold in carotid artery vein grafts harvested 4 weeks after surgery as compared with naïve inferior vena cava segments (Figure VI in the onlineonly Data Supplement). Similar to our arterial study, PAI-039 significantly inhibited vein graft intimal hyperplasia and lumen stenosis, while having no significant effect on total vessel cross-sectional area ( Figure 5 ). In addition, PAI-039 significantly decreased macrophage invasion into vein grafts, as well as SMC content within vein graft neointima ( Figure VII in the online-only Data Supplement).
PAI-039 Does Not Inhibit Endothelial Repopulation In Vivo
To determine whether the lack of an inhibitory effect of PAI-039 on EC migration in vitro was also observed in vivo, we denuded the endothelium in mouse carotid arteries by mechanical injury and used the Evans Blue dye method to quantify the effects of PAI-039 on re-endothelialization, which is mediated by EC migration from the adjacent segments of normal artery into the denuded zone. 35 PAI-039 had no significant inhibitory effect on EC migration in vivo ( Figure 6 ). In contrast, paciltaxel, which inhibits intimal hyperplasia, 36 significantly inhibited EC recovery.
Discussion
SMC migration from the tunica media to the intima results in neointima formation and is a key process in atherosclerosis, restenosis after coronary angioplasty/stent implantation, and vein graft disease. PAI-1 plays an important role in regulating SMC migration, with both pro-and anti-migratory effects being reported. 8, 11 In this study, we sought to determine the effects of pharmacological inhibition of PAI-1 on SMC migration under conditions that are relevant to human cardiovascular disease. We showed that pharmacological inhibition of PAI-1 with PAI-039 attenuates SMC, but not EC, migration in vitro. Our data suggest that PAI-039 inhibits SMC migration by downregulating LRP1-dependent STAT-1 activation. Furthermore, PAI-039 inhibits arterial and venous intimal hyperplasia and vascular inflammation without adversely affecting re-endothelialization after vascular injury.
Vitronectin is present in the vascular wall, and its expression is increased during neointima formation. [37] [38] [39] Vitronectin binds PAI-1 and regulates its function. 32 Previous studies have shown that PAI-039 effectively inhibits free, but not vitronectin-bound, PAI-1.
28,31,40 However, we have shown in this study that PAI-039 retains its antimigratory effects on SMCs in vitro in collagen matrices supplemented with vitronectin and inhibits neointima formation in vivo. In a dynamic system involving living cells or in vivo, it is likely that microenvironments exist in which free (ie, PAI-039-susceptible) PAI-1 is present because of either molar excess over vitronectin or transient dissociation from vitronectin, as occurs in an equilibrium-binding interaction. The capacity of PAI-039 to selectively inhibit free PAI-1, while bypassing active, Wild-type PAI-1 (PAI-1-WT; 0.1 μg/mL) induces translocation of STAT-1 (green) from cell cytoplasm to nuclei (blue) in murine arterial smooth muscle cells (SMCs) and wild-type mouse embryonic fibroblasts (arrows), which is inhibited by PAI-039 (25 μmol/L). In contrast, PAI-1 does not induce nuclear translocation of STAT-1 in murine endothelial cells or lowdensity lipoprotein receptor-related protein-1 (LRP1)-deficient mouse embryonic fibroblasts. Scale bar=14 μm. All images shown are representative of data from at least 2 independent experiments.
vitronectin-bound PAI-1, is intriguing and could be advantageous in the context of adverse vascular remodeling because vitronectin-bound PAI-1 inhibits cell migration by blocking vitronectin-binding interactions with its cellular receptors. 8, 9 Vitronectin-bound PAI-1 is also inhibited from binding to LRP1, a motogenic PAI-1 receptor. 41 Therefore, PAI-039 does not inhibit the antimigratory function of PAI-1, but does inhibit its pro-migratory effect by preventing its functional interaction with LRP1.
JAK/STAT-1 signaling plays an important role in regulating SMC activation and intimal hyperplasia. [42] [43] [44] PAI-1 promotes cell migration by binding LRP1 and inducing nuclear translocation of STAT-1. 11 In this study, we have shown that PAI-1 induces, while PAI-039 decreases, STAT-1 phosphorylation in SMCs. We also have demonstrated that PAI-039 inhibits PAI-1-induced STAT-1 nuclear translocation in an LRP1-dependent manner. Together with our in vitro cell migration and in vivo vascular remodeling data, our results support the hypothesis that PAI-039 exerts important inhibitory effects on LRP1/JAK/STAT-1 activation in SMCs that downregulate intimal hyperplasia. Our results, however, do not exclude the possibility that PAI-039 also targets other molecular pathways to inhibit neointima formation.
EC migration plays an essential role in restoring an intact vascular endothelium after vascular injury. In contrast to its inhibitory effect on SMC migration, PAI-039 did not significantly affect EC migration. This differential effect could be clinically significant-that is, while it is desirable to inhibit SMC migration to reduce intimal hyperplasia and vascular stenosis, concomitant inhibition of EC recovery, as occurs with currently used antirestenosis drugs, promotes thrombosis and other adverse vascular effects. Our data suggest that the nonresponsiveness of ECs to the antimigratory effect of PAI-039 may be because of their low expression level of LRP1, a finding that is consistent with published reports. 11, 45 In a previous study, we demonstrated that mice with complete PAI-1 deficiency exhibit increased vein graft intimal hyperplasia compared with WT controls. 46 We hypothesized that the enhanced neointima formation in the absence of PAI-1 resulted from (1) enhanced availability of ECM vitronectin to its cellular receptors (because of loss of binding of PAI-1 to vitronectin), which would favor cell migration, and (2) enhanced activity of proteases that are susceptible to inhibition by PAI-1, such as plasmin and thrombin, which promote intimal hyperplasia. 7, 46 Thus, it would seem paradoxical that pharmacological inhibition of PAI-1 would decrease intimal hyperplasia in the same model. Several factors may explain our results. It is known that PAI-1 has motogenic and antimotogenic effects, 8, 9, 11 both of which would be affected by genetic PAI-1 deficiency. However, it is likely that PAI-039 has a significantly greater inhibitory effect on the motogenic pool of free PAI-1 than on the antimotogenic pool of vitronectin-bound PAI-1. 31 Such a differential effect of PAI-039 could potentially produce a different net effect on intimal hyperplasia than complete genetic PAI-1 deficiency. Consistent with this hypothesis, we showed previously that PAI-1-deficient SMCs exhibit enhanced migration compared with WT SMCs 32 ; yet, as we demonstrate in the current study, PAI-039 inhibits SMC migration. Other factors may also contribute to the differential effects of genetically versus pharmacologically induced reductions in PAI-1 activity on vascular remodeling. First, it is possible that genetic deficiency of PAI-1 produces compensatory changes in the expression of other proteins that affect vein graft remodeling. Second, PAI-1 regulates enzyme activity not only in the extracellular space, but also within the intracellular environment. 20 Although genetic deficiency would affect both compartments of PAI-1, it is not known if PAI-039 inhibits intracellular PAI-1. Finally, it is possible that complete genetic deficiency of PAI-1 might produce different phenotypic effects than partial or near-complete inhibition of PAI-1, which would be expected from a pharmacological inhibitor. Of note, genetic deficiency of soluble epoxide hydrolase produced an opposite effect on cardiac fibrosis than that produced by a pharmacological inhibitor. 47 Thus, there is a precedent for genetic deficiency and pharmacological inhibition of a factor producing opposing phenotypes.
Recent studies have suggested that pharmacological PAI-1 inhibition has considerable potential as a therapeutic strategy to prevent and treat vascular diseases by pathways that are independent of fibrinolysis. TM5441, a small molecule PAI-1 inhibitor, inhibits vascular senescence and other organ dysfunction associated with aging. 30, 48 TM5275, another PAI-1 inhibitor, inhibits macrophage migration. 29 Consistent with this study, we found that PAI-039 decreased macrophage invasion into vein grafts. In contrast to our findings, Leik et al showed that PAI-039 promoted SMC migration in vitro. 40 In this study, purified PAI-1 was preincubated with PAI-039, then added to SMCs migrating on a 2-dimensional, vitronectin-coated surface. These experimental conditions, although informative regarding the potential of PAI-039 to inhibit PAI-1, probably did not adequately reproduce the physiological conditions under which SMCs migrate in vivo. A recent study showed that PAI-039 induces apoptosis of SMCs, thereby producing an antiproliferative effect,, 49 which is consistent with the known antiapoptotic properties of PAI-1. 20, 22 In addition, another recent study demonstrated that PAI-039 improved dermal wound closure in diabetic mice, 50 which is intriguing because vascular remodeling has been considered as a form of wound repair. 51 In conclusion, we have shown that pharmacological inhibition of PAI-1 with PAI-039 inhibits SMC migration and intimal hyperplasia without adversely affecting EC migration or vascular re-endothelialization. These differential effects seem to be caused by the marked difference in LRP1 expression between SMCs and ECs, with the low level of LRP1 expression in ECs shielding them from the effects of PAI-1 and PAI-039 on LRP1-induced JAK/STAT-1 signaling and cell migration. 11 Our study suggests that pharmacological targeting of PAI-1 with PAI-039, and perhaps other PAI-1 inhibitors, may be an effective strategy to treat and prevent vascular disease without disrupting EC function, which is a major limitation of currently used antirestenosis drugs. Additional studies that assess the effects of pharmacological PAI-1 inhibitors on adverse vascular remodeling in the setting of diabetes mellitus and obesity, which are associated with increased PAI-1 expression, 52, 53 and preexisting atherosclerosis are warranted. Such studies could lead to clinical trials to determine whether pharmacological PAI-1 inhibition exerts beneficial effects on human atherosclerosis, restenosis, vein graft disease, and other obstructive vascular diseases characterized by increased PAI-1 expression. 54, 55 
